Featured Research

from universities, journals, and other organizations

How should systematic reviews consider evidence on harms?

Date:
May 3, 2011
Source:
Public Library of Science
Summary:
Systematic reviews that attempt to assess the risk of harms (adverse effects) associated with specific therapies should consider a broad range of study designs, including both systematic reviews and observational studies, according to a new study.

Systematic reviews that attempt to assess the risk of harms (adverse effects) associated with specific therapies should consider a broad range of study designs, including both systematic reviews and observational studies. These are the findings of a new study, led by Su Golder of the Centre for Reviews and Dissemination, University of York, UK published in PLoS Medicine.

There is increasing focus on the importance of using rigorous methods to assess the effectiveness and harms associated with the use of new drugs and other therapies, and recognition of the role of systematic reviews in this process. A systematic review uses predefined, explicit methods to find and appraise all relevant evidence to answer a specific question in healthcare. However, there has been considerable debate as to whether systematic reviews should use evidence from randomized controlled trials or observational studies (or both) in order to collect all the relevant evidence on risk of harms. Some groups have argued that observational studies may produce biased estimates of harm, while randomized trials may be too small to generate useful data on the risk of rare adverse effects.

In the study, Golder and colleagues identified systematic reviews that had compared the risk of specific harms in evidence from randomized controlled trials versus the evidence from observational studies. They found that there was no difference on average in the estimates produced by these two approaches. The authors conclude: "Instead of restricting the analysis to certain study designs, it may be preferable for systematic reviewers of adverse effects to evaluate a broad range of studies that can help build a complete picture of any potential harm and improve the generalisability of the review without loss of validity."

This research was undertaken by Su Golder as part of an MRC fellowship. The views expressed in this presentation are those of the authors and not necessarily those of the MRC.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Su Golder, Yoon K. Loke, Martin Bland. Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview. PLoS Medicine, 2011; 8 (5): e1001026 DOI: 10.1371/journal.pmed.1001026

Cite This Page:

Public Library of Science. "How should systematic reviews consider evidence on harms?." ScienceDaily. ScienceDaily, 3 May 2011. <www.sciencedaily.com/releases/2011/05/110503171732.htm>.
Public Library of Science. (2011, May 3). How should systematic reviews consider evidence on harms?. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2011/05/110503171732.htm
Public Library of Science. "How should systematic reviews consider evidence on harms?." ScienceDaily. www.sciencedaily.com/releases/2011/05/110503171732.htm (accessed July 31, 2014).

Share This




More Science & Society News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Britain Testing Driverless Cars on Roadways

Britain Testing Driverless Cars on Roadways

AP (July 30, 2014) British officials said on Wednesday that driverless cars will be tested on roads in as many as three cities in a trial program set to begin in January. Officials said the tests will last up to three years. (July 30) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Amid Drought, UCLA Sees Only Water

Amid Drought, UCLA Sees Only Water

AP (July 30, 2014) A ruptured 93-year-old water main left the UCLA campus awash in 8 million gallons of water in the middle of California's worst drought in decades. (July 30) Video provided by AP
Powered by NewsLook.com
Texas Scientists Study Ebola Virus

Texas Scientists Study Ebola Virus

AP (July 30, 2014) Scientists in Texas are studying the Ebola virus, which has killed more than 670 people across West Africa this year. Right now, the disease has no vaccine and no specific treatment, with a fatality rate of at least 60 percent. (July 30) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins